Member Info for Retireby40

A take over requires a majority so they would’ve have nearly enough shares after conversion.

Don’t mean to be rude but who cares and now sells going through as buys which is positive as MMs taking shares above mid.

There is no RNS and no dodgy UT so the spread should open up as it closed.

I suspect we are gonna have great news early Jan as stated. I’m chilled and urban should chill too.

I suspect the news in Jan will be a significant draw for the science day. Exciting times.

I’m guessing due to the wording as urbansea89 said. Mere speculation but either way whatever the update I suspect we will have a super start to the year. 2 months to sort the science day and a good 6 weeks ahead of it there will be an update on P1a to whet the appetite.

Little point in speculating so apologies. I was more replying to urbamsea who seemed to be disappointed by the wording whereas I think it looks positive.

I’ll pipe down!

As pointed out the wording of the RNS -

progress in the ALS-6000-101 phase 1a clinical trial of AVA6000.

Progress on P1a suggests they are extending. If so they are conscious they need to give some supplementary info both to support the share price and because in June at the AGM they weren’t sure if there would be a further DE and there was so if they go for another they’ll give some sound reasoning. They’ll also want to have some solid news for the science day so if they have another DE but give info on how well it’s going it’s good news. Few side effects and lots of Dox going into TME and very little harming healthy tissue/organs.

One can hope! Either way it’s surely good news and why have a science day.

It sounds like P1a being extended so another DE. That would mean that the 4th cohort continues to have few side effects so they want to go higher. Given the first payment is due end of Jan and science day happening they will clearly give some info on the trial, how detailed remains to be seen. It would be great if they indeed confirm very few side effects and the fact the drug is cleaving so it’s working as intended and pre-clinical. AS initially wanted to publish the data once P1a was completed but he didn’t think they’d be going to a 5th cohort and realises a basic DE RNS will not cut the mustard. If the above takes place to me it’s superb news as AVA6000 is exceeding expectations. We know humans have less FAP circulating outside the TME than rodents so the targeting could be even more exquisite than pre-clinical.

It’s an anonymous BB I really wouldn’t worry about it.

Each to their own.

*I don't care about AVCT, its just another stock.

122 posts in the last 30 days suggests otherwise which is more than double the other 4 PLC BBs you post on. Given you mostly trade surely you have better things to do? Odd.

Oh and having sold 3/4 of my holding around 30p (when GB’s wife sold) I held 400k shares and then sold a fair number when there was no interim presentation. GB loves to think he can present and loves proactive so when no interviews forthcoming I knew bad news en route which was confirmed with raise rumours etc.

Anyway, best of luck to the old faithful on here. No more from me.

Having been invested for some 4 years (MWG and SKIN) and at one point held 1% of the co I had more knowledge here than most retail investors.

I’ll leave it there but all these new posters flooding this BB claiming the current share price is a bargain should pipe down.

Genuinely hope they get a decent CEO who can initiate a strategic review and start generating profit and create sustainable shareholder value.

Sadly those if us with knowledge sold some when the 3p raise rumours started (share price was 10p or so) and then sold on the first RNS. Now it’s 1.6p to buy so all those saying what a bargain it was at 3p need to pipe down.

The fact the same chairman is in place a disgrace. He should’ve gone too and I suspect he will once they find someone to take over as CEO. How long will the raise cash last given most earmarked to pay off debts.

Such a shame as great tech but GB a calamity.

I hope most of you got out well before now (hopefully after initial raise RNS). If not I genuinely hope this eventually comes good. The entire BoD a disgrace.

The market cap is less than £15m, cash of £11m at YE but they will clearly need cash and I suspect look for it in Q2. They can grow a lot without additional to their core base but clearly they struggling to convert their leads. Given it’s a new space in a very well established industry I suspect when it grows it’ll do so very quickly.

They’ll need some material deals/news to regain confidence and increase the share price. Last raise was at 40p and mostly IIs so they’ll want to protect their investments and most have held.

Being a pedant! That said the market cap is crazy and hopefully the re-rate will start before YE. Data ideally in the next 2 weeks.

Likely nearer £50m in the bank as £24m paid for Launch.

For the first time Mirriad's history, we will be airing integrations within 3 different movies, on 3 different networks, all in the same timeslot!

Tune in to ION Media Networks, Lifetime Television, and Great American Family this Sunday, December 4th at 8 pm ET to see some of our favorite holiday brand integrations in their prime time programs!

On LinkedIn

Yeah nicely dug out there Metis ;)

24 mins and 30 seconds in -

https://m.youtube.com/watch?v=lzenLmpNhxs

LONDON, UK – 17 November, 2022 - Mirriad, the leading in-content advertising company and 2022 AdExchanger Winner for Most Innovative TV Advertising Technology Award, is announcing a new in-content campaign with Pinterest and Channel 4. Pinterest’s new campaign, “Pinterest do,” will run on Channel 4’s popular “Location, Location, Location” show, which first aired on 16 November.

The campaign features virtual out-of-home signage created by Mirriad’s dynamic in-content technology in every episode this year.

The in-content placements are part of Pinterest’s “3-ways into TV” strategy, designed to increase engagement and reach: linear/VOD, dual screening and in-content via Mirriad.

“In-content advertising provides us with a creative way to expand our campaign reach. We are able to design seamless ad signage that drives the effectiveness of our larger media plan while delivering a positive viewing experience for our audience,” said Laura Taylor at Media Hub.

“We’re thrilled to work with Mirriad to bring the new Pinterest campaign to life through dynamic ad placement. Pinterest has moved beyond the boundaries of traditional advertising in a way that appeals to our viewers and increases performance,” said Chanelle Stacey at Channel 4.

“It’s a fantastic opportunity to bring Pinterest’s beautiful new campaign to life through in-content advertising. Creating unique ad experiences on an iconic Channel 4 television show demonstrates just how much top brands like Pinterest are embracing this new way of reaching audiences. It’s great to see the campaign in action” said Adam Gilsenan at Mirriad.